The HER2 protein targeted by the approved cancer drug Enhertu is found on a wide range of tumors. Interim Phase 2 data reported at the annual meeting of the American Society of Clinical Oncology suggest the AstraZeneca and Daiichi Sankyo drug has potential to treat many of these cancers.
The antibody drug, nirsevimab, is designed with a long half-life intended to protect infants from respiratory syncytial virus infection through the entire season. The drug, co-developed by AstraZeneca and Sanofi, is under FDA review.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The FDA will decide this summer which strains the next Covid-19 vaccines should address. But companies are also taking a longer view, developing shots for the future that offer different features than the current ones and potentially broader protection against a wider range of pathogens.
AstraZeneca dominates the market for drugs that treat rare blood disorder paroxysmal nocturnal hemoglobinuria. Roche drug crovalimab met the two main goals of its pivotal test, and if approved, would offer a dosing edge compared to AstraZeneca’s two blockbuster PNH medicines.
The FDA approved Airsupra, an asthma rescue inhaler that administers two different medications, one that opens up airways and another that treats inflammation. The inhaler stems from a partnership between AstraZeneca and Avillion.
Maina Bhaman, a board member of CinCor Pharma reflects on the news from Monday that AstraZeneca is acquiring the Massachusetts startup to bring another option for patients with resistant hypertension.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
AstraZeneca has committed $1.3 billion to acquire CinCor Pharma, a clinical-stage biotech whose lead drug candidate has the potential to treat hypertension in a new way. In other M&A news, Ipsen and Chiesi Farmaceutici each announced acquisitions of rare disease biotechs. All three deals come with contingent value rights.
Nearly all patients treated with the Novartis drug iptacopan achieved the hemoglobin goals of a pivotal study compared to zero patients who received the AstraZeneca drugs that are the standard of care in a rare blood disorder. The results were presented Tuesday during the annual meeting of the American Society of Hematology.
AstraZeneca is jumping into the chase for cell therapies that address solid tumors by acquiring Neogene Therapeutics. The startup’s technology can be used to discover and develop novel targets that may be able to broaden the scope of cell therapies for cancer.
FDA approval of AstraZeneca’s Imjudo comes less than three weeks after the antibody won its first approval in liver cancer. Both regulatory decisions cover use of the drug in combination with another AstraZeneca immunotherapy, Imfinzi.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
AstraZeneca already has a respiratory syncytial virus antibody drug on the market for premature babies. But the approval of Beyfortus, which was developed with Sanofi, covers all infants broadly and it protects during the entire RSV season with just a single shot.
AstraZeneca drug Imjudo is now FDA approved for treating advanced liver cancer. The infused therapy is administered under a novel dosing schedule in addition to Imfinzi, an AstraZeneca drug already approved for treating several different types of cancer.
AstraZeneca’s LogicBio acquisition comes at a critical time for the biotech. Though LogicBio has encouraging early clinical data for its lead gene-editing therapeutic candidate, the company’s cash woes include a flagging stock price that is set to lose its listing on the Nasdaq.
An Ionis Pharmaceuticals heart disease drug beat a placebo in a mid-stage clinical trial, but partner AstraZeneca has decided it won’t advance the genetic medicine to a larger Phase 3 test. The results were apparently not enough to set the Ionis therapy apart from commercialized cholesterol-lowering drugs that address the same protein target.
On the heels of receiving a landmark FDA approval in breast cancer, AstraZeneca and Daiichi Sankyo drug Enhertu won an additional approval in non-small cell lung cancer. The decision makes the drug the first targeted NSCLC therapy addressing the cancer protein HER2.